UNLABELLED: Adenosine A1 receptors (A1Rs) in human and rodent brains can be visualized with the radioligand 8-dicyclopropylmethyl-1-(11)C-methyl-3-propylxanthine ((11)C-MPDX) and PET. Here we investigated whether A1R occupancy by nonradioactive agonists and antagonists can be assessed with this technique. METHODS: Small-animal PET scans with arterial blood sampling were obtained for 4 groups of isoflurane-anesthetized Wistar rats: controls (n = 7); pretreated with a centrally active A1R agonist, N(6)-cyclopentyladenosine (CPA; 0.25 mg/kg intraperitoneally; dissociation constant, 0.48 nM; n = 7); pretreated with a moderate dose of caffeine (antagonist for A1Rs and adenosine A2A receptors; 4 mg/kg intraperitoneally; dissociation constant, 11 μM; n = 6); and pretreated with a high dose of caffeine (40 mg/kg intraperitoneally; n = 6). RESULTS: The administration of CPA resulted in a strong reduction (>50%) in the heart rate, and caffeine administration resulted in a small increase (10%-15%). A caffeine dose of 4 mg/kg (n = 6) resulted in 65.9% A1R occupancy, and a dose of 40 mg/kg (n = 6) resulted in 98.5% occupancy (calculated from a modified Lassen plot). However, the administration of CPA resulted in an increase in (11)C-MPDX binding in the brain. CONCLUSION: Small-animal PET with (11)C-MPDX can be used to assess antagonist but not agonist binding at A1Rs. Changes in tracer uptake after the administration of CPA resembled previously reported changes induced by treatment of rats with ethanol and an adenosine kinase inhibitor (ABT702). Thus, the administration of an exogenous agonist or increasing the level of an endogenous agonist have similar effects. Agonists and antagonists may bind to different sites on the A1R protein having allosteric interactions.
UNLABELLED: Adenosine A1 receptors (A1Rs) in human and rodent brains can be visualized with the radioligand 8-dicyclopropylmethyl-1-(11)C-methyl-3-propylxanthine ((11)C-MPDX) and PET. Here we investigated whether A1R occupancy by nonradioactive agonists and antagonists can be assessed with this technique. METHODS: Small-animal PET scans with arterial blood sampling were obtained for 4 groups of isoflurane-anesthetized Wistar rats: controls (n = 7); pretreated with a centrally active A1R agonist, N(6)-cyclopentyladenosine (CPA; 0.25 mg/kg intraperitoneally; dissociation constant, 0.48 nM; n = 7); pretreated with a moderate dose of caffeine (antagonist for A1Rs and adenosine A2A receptors; 4 mg/kg intraperitoneally; dissociation constant, 11 μM; n = 6); and pretreated with a high dose of caffeine (40 mg/kg intraperitoneally; n = 6). RESULTS: The administration of CPA resulted in a strong reduction (>50%) in the heart rate, and caffeine administration resulted in a small increase (10%-15%). A caffeine dose of 4 mg/kg (n = 6) resulted in 65.9% A1R occupancy, and a dose of 40 mg/kg (n = 6) resulted in 98.5% occupancy (calculated from a modified Lassen plot). However, the administration of CPA resulted in an increase in (11)C-MPDX binding in the brain. CONCLUSION: Small-animal PET with (11)C-MPDX can be used to assess antagonist but not agonist binding at A1Rs. Changes in tracer uptake after the administration of CPA resembled previously reported changes induced by treatment of rats with ethanol and an adenosine kinase inhibitor (ABT702). Thus, the administration of an exogenous agonist or increasing the level of an endogenous agonist have similar effects. Agonists and antagonists may bind to different sites on the A1R protein having allosteric interactions.
Authors: Min Guo; Abolghasem Bakhoda; Zhan-Guo Gao; Joseph M Ramsey; Yang Li; Kelly A O'Conor; Andrew C Kelleher; Seth M Eisenberg; Yeona Kang; Xuefeng Yan; Cameron Javdan; Joanna S Fowler; Kenner C Rice; Jacob M Hooker; Kenneth A Jacobson; Sung Won Kim; Nora D Volkow Journal: ACS Chem Neurosci Date: 2021-09-01 Impact factor: 5.780
Authors: Min Guo; Zhan-Guo Gao; Ryan Tyler; Tyler Stodden; Yang Li; Joseph Ramsey; Wen-Jing Zhao; Gene-Jack Wang; Corinde E Wiers; Joanna S Fowler; Kenner C Rice; Kenneth A Jacobson; Sung Won Kim; Nora D Volkow Journal: J Med Chem Date: 2018-11-13 Impact factor: 7.446
Authors: Javad Khodaii; Mostafa Araj-Khodaei; Manouchehr S Vafaee; Dean F Wong; Albert Gjedde Journal: J Nucl Med Date: 2021-06-04 Impact factor: 10.057
Authors: Amber Kerkhofs; Ana C Xavier; Beatriz S da Silva; Paula M Canas; Sander Idema; Johannes C Baayen; Samira G Ferreira; Rodrigo A Cunha; Huibert D Mansvelder Journal: Front Pharmacol Date: 2018-01-04 Impact factor: 5.810
Authors: Jürgen W A Sijbesma; Xiaoyun Zhou; David Vállez García; Martin C Houwertjes; Janine Doorduin; Chantal Kwizera; Bram Maas; Peter Meerlo; Rudi A Dierckx; Riemer H J A Slart; Philip H Elsinga; Aren van Waarde Journal: Mol Imaging Biol Date: 2016-10 Impact factor: 3.488